Cargando…

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis

Wnt signaling plays a pivotal role in maintaining bone mass. Secreted pathway modulators such as sclerostin (SOST) and Dickkopfs (DKKs) may influence bone mass inhibiting the canonical Wnt pathway. We evaluated whether bone protein content of secreted Wnt antagonists is related to age, bone mass, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueland, Thor, Stilgren, Lis, Bollerslev, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627473/ https://www.ncbi.nlm.nih.gov/pubmed/31197079 http://dx.doi.org/10.3390/ijms20122896

Ejemplares similares

Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis
por: Peng, Jia, et al.
Publicado: (2021)

Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma
por: Gerov, Vladimir, et al.
Publicado: (2023)

Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration
por: Patalong-Wójcik, Martyna, et al.
Publicado: (2023)

Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
por: Fabre, Stéphanie, et al.
Publicado: (2020)

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats
por: Suen, Pui Kit, et al.
Publicado: (2015)

Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
por: Aditya, Suruchi, et al.
Publicado: (2021)

Lrp4, a Novel Receptor for Dickkopf 1 and Sclerostin, Is Expressed by Osteoblasts and Regulates Bone Growth and Turnover In Vivo
por: Choi, Hong Y., et al.
Publicado: (2009)

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis
por: Mederle, Ovidiu Alexandru, et al.
Publicado: (2018)

Disturbed bone marrow adiposity in patients with Cushing’s syndrome and glucocorticoid- and postmenopausal- induced osteoporosis
por: Sørensen, Nina N., et al.
Publicado: (2023)

Effects of anti-sclerostin antibody and running on bone remodeling and strength
por: Toumi, H., et al.
Publicado: (2015)

Serum Dickkopf-1 Level in Postmenopausal Females: Correlation with Bone Mineral Density and Serum Biochemical Markers
por: Ahmed, Sahar Fathi, et al.
Publicado: (2013)

Suppression of Sost/Sclerostin and Dickkopf‐1 Augment Intervertebral Disc Structure in Mice
por: Kroon, Tori, et al.
Publicado: (2022)

A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures
por: Ramli, Fitri Fareez, et al.
Publicado: (2020)

Labisia pumila Prevents Complications of Osteoporosis by Increasing Bone Strength in a Rat Model of Postmenopausal Osteoporosis
por: Fathilah, Siti Noor, et al.
Publicado: (2012)

The Role of Sclerostin in Bone Diseases
por: Vasiliadis, Elias S., et al.
Publicado: (2022)

Relation of Wnt Signaling Pathway Inhibitors (Sclerostin and Dickkopf-1) to Left Ventricular Mass Index in Maintenance Hemodialysis Patients
por: Bahie, Ahmed, et al.
Publicado: (2021)

Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016)

Bone marrow adipoq(+) cell population controls bone mass via sclerostin in mice
por: Gao, Huanqing, et al.
Publicado: (2023)

Type 2 Diabetes Mellitus Increases the Risk to Hip Fracture in Postmenopausal Osteoporosis by Deteriorating the Trabecular Bone Microarchitecture and Bone Mass
por: Mohsin, Sahar, et al.
Publicado: (2019)

The role of sclerostin and dickkopf-1 in oral tissues – A review from the perspective of the dental disciplines
por: Samiei, Mohammad, et al.
Publicado: (2019)

Associations of Serum Dickkopf‐1 and Sclerostin With Cardiovascular Events: Results From the Prospective Bruneck Study
por: Klingenschmid, Gerhard, et al.
Publicado: (2020)

The Role of Sclerostin in Bone and Ectopic Calcification
por: De Maré, Annelies, et al.
Publicado: (2020)

Effects of sclerostin antibody on bone healing
por: Mihara, Atsushi, et al.
Publicado: (2021)

Treatments of osteoporosis increase bone material strength index in patients with low bone mass
por: Schoeb, M., et al.
Publicado: (2020)

Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model
por: Mohd Effendy, Nadia, et al.
Publicado: (2015)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Prevalence of primary osteoporosis and low bone mass in postmenopausal women and related risk factors
por: Hemmati, Elnaz, et al.
Publicado: (2021)

Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice
por: Williams, Diarra K, et al.
Publicado: (2017)

Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
por: Mödder, Ulrike I, et al.
Publicado: (2011)

Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
por: Stegen, Steve, et al.
Publicado: (2018)

Differential Expression of Dickkopf 1 and Periostin in Mouse Strains with High and Low Bone Mass
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2022)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2015)

Sclerostin expression in trabecular bone is downregulated by osteoclasts
por: Koide, Masanori, et al.
Publicado: (2020)

Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
por: Wang, Jialiang S., et al.
Publicado: (2021)

Obesity and Bone Loss at Menopause: The Role of Sclerostin
por: Marzullo, Paolo, et al.
Publicado: (2021)

Importance of Sclerostin as Bone-Muscle Mediator Crosstalk
por: Aryana, I Gusti Putu Suka, et al.
Publicado: (2022)

Sclerostin: clinical insights in muscle–bone crosstalk
por: Moretti, Antimo, et al.
Publicado: (2023)

Changes in expression of Wnt signaling pathway inhibitors dickkopf-1 and sclerostin before and after total joint arthroplasty
por: Lu, Ke, et al.
Publicado: (2017)

Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass
por: Gombos, Gabriella Császárné, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3kjri70ju1focaovvon2qjuvhk